HEPLISAV-B™ is NOW APPROVED

Experts in TLR Biology

We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system. Learn More >

Cancer Immunotherapy

Through our expertise in TLR biology we are developing compounds designed to stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >

‹ ›

Cancer Immunotherapy

Utilizing Toll-like Receptor biology to leverage the power of the body's immune response to stimulate multiple innate mechanisms, activating a cascade of anti-tumor activities.

Learn More ›

HEPLISAV-B is now approved

View press release

View full Prescribing Information

News

View All News

Our values

At Dynavax we are proud of the work we do. Our corporate values provide the foundation of our culture and how we operate as a company.

Learn More ›